Every 8-K that Paysign, Inc. (PAYS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PAYS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAYS filings page.
Paysign, Inc. reported record second quarter 2026 revenue of $28.25 million, up 48.1% from a year earlier, driven by strong growth in both pharma and plasma. Pharma revenue rose to $14.65 million, up 88.9%, while plasma revenue increased to $13.04 million, up 21.4%.
Profitability improved sharply, with gross margin at 63.3% and operating margin at 24.8% (21.3% excluding a fair value gain on contingent consideration). GAAP net income reached $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in Q2 2025. Adjusted EBITDA was $9.61 million, up 113.0%.
The balance sheet showed $27.37 million of unrestricted cash and no bank debt, plus $149.11 million of restricted cash. Based on first-half strength, management raised full-year 2026 guidance to revenue of $114–$117 million and Adjusted EBITDA of $35–$38 million, with higher outlooks for net income and EPS.
Paysign, Inc. held its Annual Meeting of stockholders on May 8, 2026, where shareholders voted on board elections and auditor ratification. Seven director nominees, including Mark R. Newcomer and Dennis L. Triplett, were elected to serve until the 2027 annual meeting.
Shareholders also ratified Baker Tilly US, LLP as Paysign’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 38,429,068 votes for, 279 against, and 96,029 abstentions, plus 641,671 broker non-votes.
Paysign, Inc. reported a strong first quarter of 2026, with revenue rising 50.8% to $28.04 million, driven by rapid growth in patient affordability and plasma programs. Pharma revenue grew 81.9% to $15.68 million, while plasma revenue increased 24.9% to $11.75 million.
Operating margin expanded to 23.8% from 13.4%, and net income more than doubled to $5.44 million, or $0.09 per diluted share. Adjusted EBITDA rose 113.4% to $10.59 million, with a 37.8% margin. The company ended the quarter with $20.55 million in unrestricted cash, no bank debt, and reaffirmed 2026 guidance, targeting revenue growth of 30–35% and higher margins.
Paysign, Inc. reported strong fourth quarter and full-year 2025 results, highlighted by rapid growth in its patient affordability business and expanding margins. Full-year 2025 revenues reached $82.0 million, up 40.5% from 2024, with net income of $7.55 million, or $0.13 per diluted share, nearly doubling from $3.82 million, or $0.07 per diluted share. Adjusted EBITDA grew 107.3% to $19.94 million, reflecting operating leverage as pharma revenue increased 167.8% to $33.89 million and plasma revenue rose 4.0% to $45.62 million. The company ended 2025 with $21.07 million of unrestricted cash, zero debt, higher restricted cash balances, and 595 plasma centers plus 131 active patient affordability programs. For 2026, Paysign forecasts revenue of $106.5–$110.5 million (30.0–35.0% growth), net income of $13.0–$16.0 million (or $0.21–$0.26 per diluted share), and adjusted EBITDA of $30.0–$33.0 million, supported by expected gross margins of 60.0–62.0% and continued mix shift toward higher-margin pharma programs.
Paysign, Inc. furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. Under General Instruction B-2, this information is furnished and not deemed filed under the Exchange Act. Paysign’s common stock trades on Nasdaq under ticker PAYS.
Paysign, Inc. has moved toward resolving several previously reported stockholder derivative lawsuits by entering into a Stipulation and Agreement of Settlement as a nominal defendant. The cases, all in the U.S. District Court for the District of Nevada, alleged securities law violations and related fiduciary claims, and are collectively referred to as the Derivative Actions.
On August 28, 2025, the Court set a final approval hearing for November 14, 2025 at 1:00 p.m. to decide whether the proposed settlement is fair, reasonable, and adequate and to consider any objections. If the Court grants final approval, the settlement will release all claims arising from the Derivative Actions, dismiss the cases with prejudice, and require Paysign to adopt and maintain specified corporate governance reforms. The settlement does not include any admission of fault or wrongdoing, and Paysign states that resolving the claims now is in the best interests of the company and its stockholders given the costs and risks of continued litigation.